戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 osomal rearrangements found in radio-induced papillary thyroid carcinoma.
2 lops distant metastases more frequently than papillary thyroid carcinoma.
3 thrombosis is an extremely rare condition in papillary thyroid carcinoma.
4             Of the 93 patients, 57 (61%) had papillary thyroid carcinoma.
5 by the active RET mutant, RET/PTC1, found in papillary thyroid carcinoma.
6 tic factor for the metastatic progression of papillary thyroid carcinoma.
7 BRAF gene mutation is frequently detected in papillary thyroid carcinoma.
8 iration of the mass suggested a diagnosis of papillary thyroid carcinoma.
9 stologic and cytologic similarities to human papillary thyroid carcinoma.
10 uced iodide uptake ability observed in human papillary thyroid carcinoma.
11 he peripheral blood of only one patient with papillary thyroid carcinoma.
12 pothesis that RET/PTC is sufficient to cause papillary thyroid carcinomas.
13 his oncogene has been detected only in human papillary thyroid carcinomas.
14  especially in BRAF-mutated and MET-addicted papillary thyroid carcinomas.
15 ngements are one of the genetic hallmarks of papillary thyroid carcinomas.
16  of the RET tyrosine kinase commonly seen in papillary thyroid carcinomas.
17 re believed to be tumor-initiating events in papillary thyroid carcinomas.
18  of the RET proto-oncogene detected in human papillary thyroid carcinomas.
19 d three different somatic mutations (23%) in papillary thyroid carcinomas.
20 s, are frequently found in radiation-induced papillary thyroid carcinomas.
21 as been reported to be associated with human papillary thyroid carcinomas.
22 revalent in radiation-induced post-Chernobyl papillary thyroid carcinomas.
23 is aberrant methylation is evident in 83% of papillary thyroid carcinoma, 11% of follicular thyroid c
24                     Molecular profiles of 11 papillary thyroid carcinomas, 13 follicular variant of p
25  patients were more likely to have tall-cell papillary thyroid carcinoma (6 [55%] vs 13 [18%]), multi
26 thyroid carcinomas, 13 follicular variant of papillary thyroid carcinomas, 9 follicular thyroid carci
27 tested in TPC-1 and KM12 cells, derived from papillary thyroid carcinoma and colorectal carcinoma, an
28  of cutaneous melanomas, cutaneous nevi, and papillary thyroid carcinoma and in a small fraction of o
29                             Terms related to papillary thyroid carcinoma and its treatment were used
30 e length were found in follicular variant of papillary thyroid carcinomas and follicular adenomas.
31 ion protein which is frequently expressed in papillary thyroid carcinomas and has been detected in th
32 active protein, not only in FTCs but also in papillary thyroid carcinomas and Hurthle cell carcinomas
33 (55 FA, 27 follicular thyroid carcinomas, 35 papillary thyroid carcinomas, and 22 undifferentiated th
34 reviously been implicated in pathogenesis of papillary thyroid carcinoma as a fusion partner of RET.
35 st commonly detected BRAF mutations in human papillary thyroid carcinomas (BRAF(V600E)) in thyroid fo
36 s expressed at high levels in differentiated papillary thyroid carcinomas but at low levels in anapla
37 ll lines and samples of human follicular and papillary thyroid carcinoma by reverse transcriptase-pol
38 region shared by FOXE1 and PTCSC2 in a human papillary thyroid carcinoma cell line (KTC-1) and unaffe
39                             Furthermore, the papillary thyroid carcinoma cell line could be induced t
40 ay in primary thyroid follicular cells and a papillary thyroid carcinoma cell line in vitro.
41 ransforming growth factor-beta1 (TGF-beta1), papillary thyroid carcinoma cells acquired increased can
42 pecificity of 96.2% (3 follicular variant of papillary thyroid carcinomas clustered with the benign l
43                                           In papillary thyroid carcinomas, COMET was part of a coexpr
44 icular thyroid carcinoma-derived FTC-133 and papillary thyroid carcinoma-derived BCPAP cells.
45 mphoma, chronic myelomonocytic leukaemia and papillary thyroid carcinoma described similar rearrangem
46                                          All papillary thyroid carcinomas diagnosed from 2004 to 2019
47 n, and that PRRX1 plays an important role in papillary thyroid carcinoma EMT and disease progression.
48              We demonstrated previously that papillary thyroid carcinomas exhibit aberrant patterns o
49 d tumor DNA from 17 pediatric post-Chernobyl papillary thyroid carcinomas for mutations at three diff
50                               Like the other papillary thyroid carcinoma forms of Ret, Ret/ptc2 is ac
51                               A patient with papillary thyroid carcinoma had stable disease for more
52 c findings indicated MTC for 12 patients and papillary thyroid carcinoma in 2.
53 d a remarkable increase in radiation-induced papillary thyroid carcinoma in children and young adults
54                                              Papillary thyroid carcinomas in humans are associated wi
55 yroid carcinoma oncogene (RET/PTC) generates papillary thyroid carcinomas in one genetic step.
56                 After the Chernobyl accident papillary thyroid carcinoma incidence increased in child
57  thyroidectomy caused by local recurrence of papillary thyroid carcinoma is extremely rare.
58                                              Papillary thyroid carcinoma is frequently multifocal.
59 d demonstrate that alternative exon usage in papillary thyroid carcinomas is restricted primarily to
60 ons drive differential pathway activation in papillary thyroid carcinomas, leading to different tumor
61  patients thyroidectomized for follicular or papillary thyroid carcinoma may represent the thymus.
62 ovel strategies to prevent or to treat human papillary thyroid carcinomas, MEN 2 disease, as well as
63 X) models (five colorectal carcinoma and two papillary thyroid carcinoma models) with different KRAS,
64 MDS, and both solid tumors (osteosarcoma and papillary thyroid carcinoma) occurred in recipients of D
65                Current evidence suggests the papillary thyroid carcinoma oncogene (RET/PTC) generates
66 epithelial cells were microinjected with the papillary thyroid carcinoma oncogene (RET/PTC1 short iso
67                                              Papillary thyroid carcinoma overexpress transforming gro
68  of invasive encapsulated follicular variant papillary thyroid carcinomas (P < .001).
69                                    Pediatric papillary thyroid carcinoma (PPTC) is clinically distinc
70                    A substantial increase in papillary thyroid carcinoma (PTC) among children exposed
71 ological examination of the mass confirmed a papillary thyroid carcinoma (PTC) and enlarged metastati
72 es of nonmedullary thyroid carcinoma, namely papillary thyroid carcinoma (PTC) and follicular thyroid
73  protein RET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia
74  neoplasms commonly found among adults, with papillary thyroid carcinoma (PTC) being the most prevale
75  observed that 63 of 110 (57%) human primary papillary thyroid carcinoma (PTC) cases expressed nuclea
76                                              Papillary thyroid carcinoma (PTC) demonstrates significa
77  MTC and follicular tumours resembling human papillary thyroid carcinoma (PTC) depending on the found
78                                              Papillary thyroid carcinoma (PTC) displays higher herita
79                                              Papillary thyroid carcinoma (PTC) displays strong but so
80                                     Although papillary thyroid carcinoma (PTC) displays strong herita
81 mph node metastasis (LNM) from N1b to N1a in papillary thyroid carcinoma (PTC) has sparked debate due
82   Many patients undergoing thyroidectomy for papillary thyroid carcinoma (PTC) have subclinical nodal
83 nobyl nuclear power plant accident increased papillary thyroid carcinoma (PTC) incidence in surroundi
84                                              Papillary thyroid carcinoma (PTC) incidence increased af
85                                              Papillary thyroid carcinoma (PTC) is clinically heteroge
86                                              Papillary thyroid carcinoma (PTC) is one of the most com
87                       The tumor ecosystem of papillary thyroid carcinoma (PTC) is poorly characterize
88                                              Papillary thyroid carcinoma (PTC) is the most common his
89                                              Papillary thyroid carcinoma (PTC) is the most common typ
90                                Biomarkers of papillary thyroid carcinoma (PTC) metastasis can accurat
91           A genome-wide association study of papillary thyroid carcinoma (PTC) pinpointed two indepen
92                                              Papillary thyroid carcinoma (PTC) remained to be the mos
93 posure from the Chornobyl accident increased papillary thyroid carcinoma (PTC) risk.
94  variants associated with the development of papillary thyroid carcinoma (PTC) that can be used to co
95 gy (TCM) is a rare and aggressive variant of papillary thyroid carcinoma (PTC) that has been associat
96    Approximately 40 percent of patients with papillary thyroid carcinoma (PTC) typically have either
97   Historically, only 40% to 50% of childhood papillary thyroid carcinoma (PTC) were known to be drive
98                                Patients with papillary thyroid carcinoma (PTC) with lateral neck meta
99 600E) is the most common somatic mutation in papillary thyroid carcinoma (PTC), how it induces tumor
100                Thyroid cancer, predominantly papillary thyroid carcinoma (PTC), is common, but an est
101                            One such disease, papillary thyroid carcinoma (PTC), is the leading endocr
102                                              Papillary thyroid carcinoma (PTC), the most frequent thy
103 rticularly those associated with a precursor papillary thyroid carcinoma (PTC).
104 earrangements, which are frequently found in papillary thyroid carcinoma (PTC).
105 young age at exposure and risk of developing papillary thyroid carcinoma (PTC).
106 tively little is known about the genetics of papillary thyroid carcinoma (PTC).
107 NP (rs965513) firmly associated with risk of papillary thyroid carcinoma (PTC).
108 ral soluble factors that were induced by RET/papillary thyroid carcinoma (PTC)3 gene expression inclu
109                    Genetic analysis of human papillary thyroid carcinomas (PTC) has revealed unique c
110                                         Most papillary thyroid carcinomas (PTC) have an isozyme-speci
111  sequencing and expression analysis of eight papillary thyroid carcinomas (PTC) to comprehensively ch
112 ted BRAF is detected in approximately 45% of papillary thyroid carcinomas (PTC).
113 ion is the most common genetic alteration in papillary thyroid carcinomas (PTC).
114  is the most prevalent genetic alteration in papillary thyroid carcinomas (PTC).
115 he number of genetic alterations detected in papillary thyroid carcinomas (PTC).
116                                              Papillary thyroid carcinomas (PTCs) account for 90% of h
117  prognostication and treatment selection for papillary thyroid carcinomas (PTCs) do not uniformly pre
118                                              Papillary thyroid carcinomas (PTCs) that invade into loc
119 95 sporadic thyroid tumors, of which 39 were papillary thyroid carcinomas (PTCs), 12 were follicular
120  occurs in various thyroid neoplasms such as papillary thyroid carcinomas (PTCs), follicular thyroid
121 is the most common endocrine malignancy, and papillary thyroid carcinoma represents the most common t
122 tive activation of the RET proto-oncogene in papillary thyroid carcinomas results from rearrangements
123 embers of the rearranged during transfection/papillary thyroid carcinoma (RET/PTC) fusion oncogene fa
124 ing RET chimeric oncoproteins found in human papillary thyroid carcinomas (RET/PTC) as well as RET on
125 ess risk, 15.27 per 10 000 person-years) and papillary thyroid carcinoma (SIR, 5.26 [95% CI, 3.25-8.0
126 tergenic, noncoding RNA gene (lincRNA) named Papillary Thyroid Carcinoma Susceptibility Candidate 3 (
127                                              Papillary thyroid carcinomas that invade locally or meta
128 id-targeted expression of ret/PTC1 developed papillary thyroid carcinomas that were minimally invasiv
129                      Combi-TA mice developed papillary thyroid carcinomas, the incidence of which was
130 s strongly correlated with the generation of papillary thyroid carcinomas, the most prevalent maligna
131 ssed cDNA fragments were isolated from human papillary thyroid carcinoma tissues, among them a cDNA w
132     To gain insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of
133                             We conclude that papillary thyroid carcinoma tumor cells exhibit increase
134     In this cohort study among patients with papillary thyroid carcinomas up to 4 cm, ATA guideline c
135                         None of the cases of papillary thyroid carcinoma was positive for ras oncogen
136                                      Classic papillary thyroid carcinoma was the most common histolog
137 sidual neck thyroid tissues of patients with papillary thyroid carcinoma were quantified.
138 ents with oncologic diseases (breast cancer, papillary thyroid carcinoma) were injected intravenously
139 nscripts were associated with follicular and papillary thyroid carcinomas, whereas long telomeres and
140                          We report a case of papillary thyroid carcinoma which invades IJV with hyper
141 HB/SDHD mutation carriers have renal cell or papillary thyroid carcinomas, which are also CS-related
142 es and transcriptomes of pediatric and adult papillary thyroid carcinoma, with implications for under
143  mutations in p53 were found by SSCP in 2/33 papillary thyroid carcinomas, with one missense mutation

 
Page Top